ApollomicsAPLMW +44.60%31 Quick Ratio is 0.96 as of Dec. 2025, which is 74% below its 10-year median of 3.73. GuruFocus rates APLMW with a GF Score™ of 31/100. The stock has 5 warning signs investors should review. Among 1,412 Biotechnology companies, Apollomics ranks worse than 81.87% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Apollomics's quick ratio for the quarter that ended in Dec. 2025 was 0.96.
Apollomics has a quick ratio of 0.96. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for Apollomics's Quick Ratio or its related term are showing as below:
APLMW'
s Quick Ratio Range Over the Past 10 Years
Min: 0.96 Med: 3.73 Max: 13.05
Current: 0.96
During the past 6 years, Apollomics's highest Quick Ratio was 13.05. The lowest was 0.96. And the median was 3.73.
APLMW's Quick Ratio is ranked worse than 81.87% of 1412
companies
in the Biotechnology industry
Industry Median: 3.6
vs APLMW: 0.96
Apollomics (NAS:APLMW) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Apollomics Quick Ratio Related Terms
Apollomics Quick Ratio Historical Data
* Premium members only.
The historical data trend for Apollomics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Apollomics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apollomics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Apollomics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Apollomics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Apollomics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apollomics (APLMW) has a Quick Ratio of 0.96 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Apollomics and its competitors. This is 74% below median its historical median of 3.73. Over the past decade, Apollomics' Quick Ratio has ranged from 0.96 to 13.05. According to the industry distribution chart, Apollomics ranks #1156 out of 1412 companies in the Biotechnology industry, placing it in the top 81.9%.
Is Apollomics' Quick Ratio too high?
Apollomics' current Quick Ratio of 0.96 is 74% below median its 10-year median of 3.73. Over the past 10 years, this metric has ranged from a low of 0.96 to a high of 13.05. The Biotechnology industry median Quick Ratio is 3.60. Apollomics' value of 0.96 is 73.3% below this industry median. Based on the distribution chart, Apollomics ranks #1156 out of 1412 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Apollomics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Apollomics' Quick Ratio compare to HYPD and MGX?
According to the Biotechnology industry distribution chart, Apollomics ranks #1156 out of 1412 companies for Quick Ratio. This places Apollomics in the lower half of its industry. The industry median Quick Ratio is 3.60. Apollomics' value of 0.96 is 73.3% below this benchmark. Historically, Apollomics' own Quick Ratio has ranged from 0.96 to 13.05 over the past decade. While the company's 10-year median is 3.73 vs. the industry median of 3.60, Apollomics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Apollomics's current Quick Ratio of 0.96 is 73.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Apollomics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apollomics's current Quick Ratio is 0.96, which is 74% below median its own 10-year median of 3.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apollomics stock overvalued right now?
Apollomics (APLMW) has a current Quick Ratio of 0.96. The current Quick Ratio is 0.96, which is 74% below median its 10-year median of 3.73 and 73.3% below the Biotechnology industry median of 3.60. Apollomics' overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Apollomics (APLMW), the current Quick Ratio is 0.96 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.
31GF Score
Get the complete analysis for APLMW
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APLMW has been successfully added to your 
